Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.
Antonello, Zeus A, Nancy Hsu, Manoj Bhasin, Giovanni Roti, Mukta Joshi, Paul Van Hummelen, Emily Ye, et al. 2017. “Vemurafenib-Resistance via de Novo RBM Genes Mutations and Chromosome 5 Aberrations Is Overcome by Combined Therapy With Palbociclib in Thyroid Carcinoma With BRAFV600E.”. Oncotarget 8 (49): 84743-60.